MAPT and Alzheimer disease: Since 2007, multiple guidelines have pointed to the crucial role of Aβ and tau biomarkers in the accurate diagnosis of AD, both for research purposes [[28], [29], [30], [31], [32], [33], [34], [35]] and, more recently, clinical practice [15,36,37].